LipoxenLipoxen, a biopharmaceutical company, has entered into an agreement with Glide Pharma, a specialty pharmaceutical company, to investigate the delivery of Lipoxen's long-acting proprietary insulin, SuliXen, which is a conjugate of insulin with polysialic acid, using the Glide SDI.

Under the terms of the agreement, Lipoxen will provide Glide Pharma with SuliXen which Glide Pharma will then incorporate into its proprietary Glide SDI, needle-free, drug delivery technology which offers the prospect of a safe, patient-friendly, solution for the administration of drugs and vaccines. Financial details were not disclosed.

According to Lipoxen, SuliXen has already shown to be safe and well tolerated in a Phase I study and the long-acting formulation of SuliXen makes this approach very attractive for the administration of insulin.

This needle-free injection could also be a key competitive advantage for SuliXen as it would meet the clear demand from patients and physicians for improved forms of insulin, which have, in particular, more patient convenience, the company said.
Scott Maguire, CEO of Lipoxen, said: "This transaction highlights our ability to execute collaboration deals with very real commercial potential. The needle-free delivery will open up a wide range of therapeutic options for our candidates and would provide further validation of the possible wide application of Lipoxen's proprietary PolyXen molecules."